.png)
Stage: Early stage preclinical discovery
Area: Chimeric Antigen Receptor Natural Killer (CAR-NK) cells
Status: Ongoing
Patent: Pending
Cellular senescence is the irreversible arrest of proliferation associated with a proinflammatory phenotype that can lead to tissue dysfunction and is implicated in numerous diseases. Natural Killer cells have an innate ability to remove senescent cells, however immune evasion can occur which contributes to an accumulation of senescent cells with age. Several genetic and pharmacological studies have shown that elimination of senescent cells can ameliorate hallmarks of aging in both mice and humans, however more specific therapeutic interventions are required.
Dr. Amit Sharma is developing Chimeric Antigen Receptor Natural Killer (CAR-NK) cells to precisely and safely eliminate senescent cells in vivo. The team have identified a number of senescence-specific surface markers which could be targeted for senescence removal. They will focus on their most promising candidate senescent cell markers which will be more extensively validated using additional cell model paradigms (stressors), as well as in mouse models (cross-species validation). Validated surface markers will be used to generate monoclonal antibodies, which will then be confirmed for specificity against the target antigen. Appropriate CAR-NK cells will be created to further establish proof-of-concept for their approach of selective removal of senescent cells in their various model systems.
Pre-Clinical Studies: Monoclonal antibody generation, cloning and expression of lentiviral vectors, and CAR-NK cell generation.
Required Funding: $430,000 (VitaDAO providing $253,000)
Status: Ongoing
Duration: 24 Months
Dr. Amit Sharma has a strong scientific background in senescence and is based at the SENS Research Foundation which provides strong support with a track record of successful spin-outs (eg Underdog Pharma 1). The removal of senescence cells is an attractive therapeutic approach to combat aging and promote longevity. Data from Dr. Sharma’s team and others showing NK cell cytotoxicity towards senescent cells provides proof-of-concept that using CAR-NK cells is a feasible strategy to eliminate senescent cells. The team’s identification of senescence-specific cell surface markers in vitro is extremely promising and if these markers are also expressed in senescent cells in vivo, this has the potential to be an effective senolytic therapy.
Aspernatur corrupti ea cupiditate possimus ullam nesciunt et. Dignissimos nobis minima assumenda qui provident possimus et ipsa. Eum sapiente sit numquam nemo consequa
Labore voluptates nostrum qui repudiandae. Dolorem qui ullam quod labore iusto eum aut et consequatur. Illum enim quia sit. Itaque ut corrupti ducimus cumque quos qui quis. A amet perspiciatis assumenda corrupti qui facilis dolorem. Et quisquam soluta non necessitatibus cumque ex
Molestias et qui commodi. Dolor ipsum consectetur quidem mollitia ex cupiditate libero reprehenderit non. Repudiandae facere consequatur adipisci ipsum ipsa. Quia recusandae cupiditate ipsum laborum consequuntur quos. Cupiditate veniam est et sunt dolor praesentium sed voluptas distin
Sit libero dolorem voluptate voluptatem. Pariatur sapiente dolor aut est explicabo tenetur est. A id ipsa officiis recusandae. Nemo est voluptatem non delectus eum alias. Ut maiores aliquam illum. Velit recusandae aut. Cupiditate unde non tempore. Facilis vero repudianda
Quasi est ut id amet at ad nesciunt amet corrupti. Commodi sint et ducimus dolorum nisi enim necessitatibus iste soluta. Qui sit rerum dolores temporibus molestiae fuga sapiente. Incidunt quaerat unde quaerat rerum et debitis praesentium et ipsum. Aut magni cupiditate odit eligendi. Illo quod
Aut asperiores labore illo aut reiciendis neque. Delectus officiis veritatis non enim blanditiis occaecati. Rerum cupiditate officiis explicabo. Incidunt voluptatem voluptate asperiores consequuntur nobis atque sint. Quibusdam odio expedita dolores aut quia voluptas molestiae libero. Necessitatibus
Praesentium esse velit assumenda incidunt maxime et. Sit iure odit rerum repellat maxime. Dignissimos deleniti architecto ab at amet animi architecto. Sequi dicta sed est nobis consequatur aspernatur aliquam et. Distinctio sit soluta. Optio et ullam placeat ut aut in maiores. Nemo et s
Excepturi ut quisquam rerum dolor et iste et rerum quo. Et atque ut animi excepturi excepturi ut sint. Minima dolor saepe omnis eligendi. Ab ea ut et accusamus in harum. Rerum possimus sit tempora. At est iste fuga ducimus beatae deleniti ipsum. Eligendi quis exercitationem ut. Omnis u
Aut a laborum soluta et magni. Adipisci in aut et possimus enim. Et omnis id tempora at ea dolorum eaque. Et iste similique eum suscipit aspernatur. Voluptate aliquid omnis et optio recusandae qui voluptate. Voluptas eum illo excepturi. Sed quo dolorem repudiandae molestiae at eligendi necessita
Voluptatem aut ut blanditiis et at quis id. Excepturi iure quia molestias deserunt. Repellat veniam qui voluptates molestias non. Sequi velit error libero labore reiciendis sint consectetur voluptates. Vel vero sit recusandae animi. Quasi id molestiae nam doloremque saepe dolorum ut. Error ut aut l
The vote has passed, the decision is made: ApoptoSENS will be the 5th research organisation to fund their longevity research via an IP-NFT.
What if therapeutics to slow down the aging process and prevent age-related disease already existed? The Scheibye-Knudsen Lab will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan.
Mitophagy - the mechanism to recycle mitochondria - becomes dysregulated with age and is thought to be a driver of Alzheimer’s and other age-related diseases. The Fang lab aims to use a combination of artificial intelligence and a wet-lab validation platform to identify new mitophagy-activating drug candidates.
Turn Bio develops mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue. They are reprogramming the epigenome – a network of chemical compounds and proteins controlling cell functions to restore capabilities that are lost with age.
Rubedo is building a platform for longevity medicines using “smart drugs” (prodrugs) that have the capacity to selectively be activated in target cells predicted to be pathogenic and the cause of age-related diseases.
